Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 187 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PARP Inhibitor Clear all

Conditions: Refractory Solid Tumors, Cancer Tumor
Interventions: AZD2461; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions: Olaparib, Physician's choice chemotherapy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 42
States / cities: San Diego, California • Santa Rosa, California • Whittier, California + 35 more

Conditions: Ovarian Neoplasms
Interventions: Niraparib, TSR-042, Bevacizumab, Carboplatin, Paclitaxel; Drug · Biological
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more

Conditions: BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Epithelial Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Laboratory Biomarker Analysis, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 153
States / cities: Phoenix, Arizona • Concord, California • La Jolla, California + 114 more

Conditions: High Grade Serous Carcinoma
Interventions: Olaparib Pill, AZD6738; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Prostatic Neoplasms
Interventions: Niraparib; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • Riverside, California + 20 more

Conditions: Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer, Prostate Cancer, NSCLC, Pancreatic Cancer, Colorectal Cancer
Interventions: TALZENNA capsule, Talazoparib soft gel capsule; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 23
States / cities: Encinitas, California • Los Angeles, California • San Marcos, California + 12 more

Conditions: Ovarian Cancer, Breast Cancer
Interventions: BKM120 and Olaparib, BYL719 and Olaparib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Colorectal Neoplasms, Breast Neoplasms
Interventions: Olaparib, Cediranib, Durvalumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumors
Interventions: E7016 + TMZ; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Boston, Massachusetts • Lebanon, New Hampshire • Greenville, South Carolina + 2 more

Conditions: Neoplasms
Interventions: ABT-888, Carboplatin, Paclitaxel; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 110 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Bethesda, Maryland • Pittsburgh, Pennsylvania

Conditions: Recurrent Ovarian Cancer
Interventions: CPI-0209, carboplatin; Drug
Lead sponsor: Lan Coffman; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine
Interventions: Olaparib, Durvalumab, EKG, Tumor biopsy, CT chest, abdomen and pelvis, MRI chest, abdomen and pelvis; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Olaparib 300mg tablets, Placebo to match olaparib 300mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 16
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: ZEN003694, Talazoparib; Drug
Lead sponsor: Alexander B Olawaiye, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma, Urinary Bladder Carcinoma, Urethra Carcinoma, Muscle Invasive Bladder Cancer
Interventions: Rucaparib; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 41
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 35 more

Conditions: Ewing Sarcoma
Interventions: niraparib, Temozolomide, Irinotecan; Drug
Lead sponsor: Sarcoma Alliance for Research through Collaboration; Other
Eligibility: 13 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 4
States / cities: Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more

Conditions: Pancreatic Cancer, Pancreatic Acinar Carcinoma
Interventions: SNV1521, daraxonrasib; Drug
Lead sponsor: ParVation Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer, Gastric Cancer, Solid Tumors
Interventions: Veliparib, Carboplatin, Paclitaxel, FOLFIRI; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Scottsdale, Arizona • San Antonio, Texas

Conditions: Advanced Solid Tumors (Excluding Prostate Cancer), Ovarian Cancer
Interventions: Elimusertib (BAY1895344), Niraparib; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Triple Negative Breast Cancer
Interventions: Olaparib Oral Product, Olaparib Oral Product in combination with Durvalumab; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ovarian, Breast, SCLC, Gastric Cancers
Interventions: Olaparib, MEDI4736, Bevacizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 7
States / cities: Newnan, Georgia • Towson, Maryland • Boston, Massachusetts + 4 more

Conditions: Acute Myeloid Leukemia
Interventions: Decitabine, talazoparib; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer
Interventions: Talazoparib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 14
States / cities: Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 4 more

Search by objective public record fields.

An Open-Label, Dose-Escalation Study of AZD2461

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

Decitabine and Talazoparib in Untreated AML and R/R AML

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors